Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: No involvement of CD80 in tumor control

Oncotarget

Volumn 8, Issue 16, 2017, Pages 26771-26788

  Danishmalik, Sayyed Nilofar ^a   Lee, Si Hyeong ^a   Sin, Jeong Im ^a  

^a Kangwon National University   (South Korea)

Author keywords

Antitumor immunity; CD80; HER2; MDSCs; Tumor models

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GEMCITABINE; IMMUNOGLOBULIN G ANTIBODY; PROTEIN HER2 342-350; PROTEIN HER2 63-71; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DOXECITINE; IMMUNOGLOBULIN G; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

4T1.2 HER2 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTITUMOR IMMUNITY; ARTICLE; BIOASSAY; CANCER CONTROL; CANCER MODEL; CARCINOGENICITY; CD8+ T LYMPHOCYTE; CELL DEPLETION ASSAY; CELL FUNCTION; CELL LINE; CELL SPECIFICITY; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; FEMALE; GENE INACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOCOMPETENT CELL; LYMPH NODE; LYMPHOCYTE DEPLETION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PROTEIN EXPRESSION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR DRAINING LYMPH NODE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; DRUG EFFECT; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NEOPLASM; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIGENS, NEOPLASM; BIOMARKERS; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; FEMALE; GEMCITABINE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; MICE, KNOCKOUT; NEOPLASMS; RECEPTOR, ERBB-2; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TUMOR BURDEN;

EID: 85017505489     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15816     Document Type: Article

References (45)

1. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986; 319:226-30
2. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986; 232:1644-6
3. Slamon, DJ, Clark, GM, Wong, SG, Levin, WJ, Ullrich, A, McGuire, WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235:177-82
4. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer. 1990; 45:457-61
5. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997; 57:1199-205
6. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994; 54:16-20
7. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neuderived peptide. Proc Natl Acad Sci USA. 1995; 92:432-6
8. Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, Moluçon C, Tubiana N, Causeret S, Misset JL, Feutray S, Mery-Mignard D, Garnier J, et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol. 2006; 17:409-14
9. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006; 24:2786-92
10. O'Sullivan CC, Smith KL. Therapeutic considerations in treating HER2-positive metastatic breast cancer. Curr Breast Cancer Rep. 2014; 6:169-82
11. Milani A, Sangiolo D, Aglietta M, Valabrega G. Recent advances in the development of breast cancer vaccines. Breast Cancer (Dove Med Press). 2014; 6:159-68
12. Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in highrisk breast cancer patients. Ann Oncol. 2014; 25:1735-42
13. Piechocki M, Pilon SA, Wei WZ. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol. 2001; 167:3367-74
14. Lee JY, Kim DH, Chung Y, Shin SU, Kang CY. Comparison of the antitumor efficacies of Her-2/neu DNA vaccines inducing contrasting IgG immunity but comparable CTL activity in mice. Vaccine. 2003; 21:521-31
15. Foy SP, Mandl SJ, Dela Cruz T, Cote JJ, Gordon EJ, Trent E, Delcayre A, Breitmeyer J, Franzusoff A, Rountree RB. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Cancer Immunol Immunother. 2016; 65:537-49. doi: 10.1007/s00262-016-1816-7
16. Foy TM, Bannink J, Sutherland RA, McNeill PD, Moulton GG, Smith J, Cheever MA, Grabstein K. Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. Vaccine. 2001; 19:2598-606
17. Park JM, Terabe M, Steel JC, Forni G, Sakai Y, Morris JC, Berzofsky JA. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Res. 2008; 68:1979-87
18. Kershaw MH, Jackson JT, Haynes NM, Teng MW, Moeller M, Hayakawa Y, Street SE, Cameron R, Tanner JE, Trapani JA, Smyth MJ, Darcy PK. Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol. 2004; 173:2143-50
19. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, Nakamura H, Furukawa K, Kanematsu T, Shiku H. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol. 1997; 159:1336-43
20. Nguyen-Hoai T, Kobelt D, Hohn O, Vu MD, Schlag PM, Dörken B, Norley S, Lipp M, Walther W, Pezzutto A, Westermann J. HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: Gene gun is superior to jet injector in inducing CTL responses and protective immunity. Oncoimmunol. 2012; 1:1537-45
21. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Ann Rev Immunol. 2002; 20:29-53
22. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002; 2:116-126
23. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spiggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med. 1993; 178:669-674
24. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994; 180:1263-1272
25. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA. 1992; 89:6550-6554
26. Shu U, Kiniwa M, Wu CY, Maliszewski C, Vezzio N, Hakimi J, Gately MK, Delespesse G. Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur J Immunol. 1995; 25:1125-1128
27. Kato T, Hakamada R, Yamane H, Nariuchi H. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J Immunol. 1996; 156:3932-3938
28. Danishmalik SN, Lee SH, Sin JI. A lack of antitumor therapeutic control of HER2 DNA vaccines is associated with myeloid-derived suppressor cells in tumor tissues in a HER2-expressing tumor model. Submitted for publication
29. Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS, Sin JI. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res. 2002; 62:7234-7240
30. Sin JI. Suppression of antitumor protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 cDNA: involvement of nitric oxide in immune suppression. Immunol. 2009; 128:e707-e717
31. Sin JI, Hong SH, Park YJ, Park JB, Choi YS, Kim MS. Antitumor therapeutic effects of E7 subunit and DNA vaccines in an animal cervical cancer model: antitumor efficacy of E7 therapeutic vaccines is dependent on tumor sizes, vaccine doses, and vaccine delivery routes. DNA & Cell Biol. 2006; 25:277-286
32. Ahn E, Kim H, Han KT, Sin JI. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Agspecific CTLs in a colon cancer model. Cancer Lett. 2015; 356:676-85
33. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Chaudhury AR, La Perle KM, Kreiner M, Young G, Guttridge DC, et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res. 2011; 71:5101-10
34. Strehl B, Seifert U, Krüger E, Heink S, Kuckelkorn U, Kloetzel PM. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev. 2005; 207:19-30
35. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015; 112:1501-9
36. Cho HI, Lee YR, Celis E. Interferon gamma limits the effectiveness of melanoma peptide vaccines. Blood. 2011; 117:135-144
37. Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res. 2007; 13:341-349
38. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9:162-74
39. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010; 184:3106-16
40. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010; 70:68-77
41. Lee SH, Danishmalik SN, Sin JI. DNA vaccines, electroporation and their applications in cancer treatment. Human Vaccines & Immunother. 2015; 11:1889-900
42. Penichet ML, Challita PM, Shin SU, Sampogna SL, Rosenblatt JD, Morrison SL. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci. 1999; 49:179-88
43. 180-188 peptides. Cancer Immunol Immunother. 2012; 61:1671-82
44. Sin JI, Kim H, Ahn E, Jeon YH, Park WS, Lee SY, Kwon B. Combined stimulation of TLR9 and 4-1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTLs and their infiltration into tumor sites. Cancer Lett. 2013; 330:190-9
45. Sin JI, Sung JH, Suh YS, Lee AH, Chung JH, Sung YC. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of co-injection with a granulocyte,macrophagecolony stimulating factor gene. Vaccine. 1997; 15:1827-33